leqembi eisai news - Search News

Eisai, Alzheimer's and Biogen

FiercePharma · 1d

EMA changes tune, endorses Eisai and Biogen's Leqembi in restricted Alzheimer's population

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | Upon reexamination, the EMA has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi.

BioPharma Dive · 1d

Eisai wins over European regulators on Alzheimer’s drug Leqembi

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

Reuters on MSN · 1d

EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatment.

Zacks.com on MSN8h

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe

Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...

EU regulators endorse meds from BMS, J&J, Eisai and more—plus a clutch of biosims

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Leqembi Okayed for Subset of Early Alzheimer’s Patients

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

4d

Eisai: Still Relatively Modest Market-Implied Expectations For Leqembi

Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...

GlobalData on MSN7d

Eisai lowers Leqembi revenue forecast after rocky entry to market

Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results